» Articles » PMID: 16131493

The Short Apical Membrane Half-life of Rescued {Delta}F508-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Results from Accelerated Endocytosis of {Delta}F508-CFTR in Polarized Human Airway Epithelial Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2005 Sep 1
PMID 16131493
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

The most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in individuals with cystic fibrosis, DeltaF508, causes retention of DeltaF508-CFTR in the endoplasmic reticulum and leads to the absence of CFTR Cl(-) channels in the apical plasma membrane. Rescue of DeltaF508-CFTR by reduced temperature or chemical means reveals that the DeltaF508 mutation reduces the half-life of DeltaF508-CFTR in the apical plasma membrane. Because DeltaF508-CFTR retains some Cl(-) channel activity, increased expression of DeltaF508-CFTR in the apical membrane could serve as a potential therapeutic approach for cystic fibrosis. However, little is known about the mechanisms responsible for the short apical membrane half-life of DeltaF508-CFTR in polarized human airway epithelial cells. Accordingly, the goal of this study was to determine the cellular defects in the trafficking of rescued DeltaF508-CFTR that lead to the decreased apical membrane half-life of DeltaF508-CFTR in polarized human airway epithelial cells. We report that in polarized human airway epithelial cells (CFBE41o-) the DeltaF508 mutation increased endocytosis of CFTR from the apical membrane without causing a global endocytic defect or affecting the endocytic recycling of CFTR in the Rab11a-specific apical recycling compartment.

Citing Articles

Cell type-specific regulation of CFTR trafficking-on the verge of progress.

Farinha C, Santos L, Ferreira J Front Cell Dev Biol. 2024; 12:1338892.

PMID: 38505263 PMC: 10949533. DOI: 10.3389/fcell.2024.1338892.


In Silico and In Vitro Evaluation of the Mechanism of Action of Three VX809-Based Hybrid Derivatives as Correctors of the F508del CFTR Protein.

Baroni D, Scarano N, Ludovico A, Brandas C, Parodi A, Lunaccio D Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139828 PMC: 10748060. DOI: 10.3390/ph16121702.


Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.

Bongiorno R, Ludovico A, Moran O, Baroni D Int J Mol Sci. 2023; 24(16).

PMID: 37629017 PMC: 10454486. DOI: 10.3390/ijms241612838.


YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1.

Barros P, Matos A, Matos P, Jordan P Biomolecules. 2023; 13(6).

PMID: 37371529 PMC: 10296715. DOI: 10.3390/biom13060949.


Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.

Stanke F, Pallenberg S, Tamm S, Hedtfeld S, Eichhorn E, Minso R Front Pharmacol. 2023; 14:1114584.

PMID: 36778025 PMC: 9911415. DOI: 10.3389/fphar.2023.1114584.